First-line Dasatinib Plus Conventional Chemotherapy in Adults With Newly Diagnosed Ph-Positive ALL

Inclusion Criteria:

* Patients with newly diagnosed acute lymphoblastic or biphenotypic leukemia (karyotypic or molecular evidence of Ph)
* Ages of 15-65 years
* Eastern Cooperative Oncology Group performance status of 0-2
* Adequate renal (serum creatinine less than 2 mg/dl, unless considered due to leukemia) and hepatic (serum bilirubin less than 3 mg/dl, unless considered due to leukemia) functions
* Adequate cardiac status (New York Heart Association Class less than or equal to 2)
* Signed informed consent

Exclusion Criteria:

* Pregnant and lactating women will not be eligible. Women of childbearing potential should have a negative pregnancy test prior to entering on the study.
* Active cardiac dysfunction (New York Heart Association Class more than or equal to 3), uncontrolled angina, myocardial infarction (within 6 months), congenital long QT syndrome, any history of clinically significant ventricular arrhythmias (such as ventricular tachycardia or ventricular fibrillation), or prolonged QTc interval on pre-entry electrocardiogram (more than 470 msec)
* Patients with documented significant pleural or pericardial effusions unless they are thought to be secondary to their leukemia
* Patients with severe medical conditions that in the view of the investigator prohibits participation in the study
* Treatment with any other investigational antileukemic agents in the last 30 days before study entry